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Summary The aim of this phase study was to determine the maximum tolerated dose of a 3-h infusion of paclitaxel, combined with
carboplatin at a fixed AUC of 7 mg ml-'min every 4 weeks for up to six cycles and to evaluate any possible pharmacokinetic interaction.
Twelve chemonaive patients with ovarian cancer were treated with paclitaxel followed by a 30-min infusion of carboplatin. Paclitaxel dose was
escalated from 150 mg m-2 to 225 mg m-2 in cohorts of three patients. Carboplatin dose was based on renal function. Pharmacokinetic studies
were performed in nine patients (at least two at each dose level). A total of 66 courses were evaluable for assessment. Grade 3 or 4
neutropenia was seen in 70% of the courses, however hospitalization was not required. Grade 3 or 4 thrombocytopenia occurred in 24% of
the courses. Alopecia, myalgia and peripheral neuropathy were common but rarely severe.
The pharmacokinetics of paclitaxel was non-linear and did not appear to be influenced by co-administration of carboplatin. The AUC of
carboplatin was 7.0±1.4 mg ml-' min, indicating that there was no pharmacokinetic interaction. The combination of carboplatin and paclitaxel
may be administered as first-line treatment for advanced ovarian cancer. Although myelosuppression is the dose-limiting toxicity of the
component drugs, the severity of thrombocytopenia was less than anticipated. The results of this study, with only a small number of patients,
need to be confirmed in future investigations.
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For the past two decades, efforts have been made to improve the
treatment of ovarian cancer, but results remain far from ideal.
Radical debulking surgery alone is not curative and chemotherapy
is required for the majority of patients. Of the chemotherapy
agents used, platinum-based regimens have proved to be the most
effective (Advanced Ovarian Cancer Trial Group, 1991). These
drugs, given as first-line therapy, induce responses in 50-60% of
patients, but in a majority ofresponding patients the tumour even-
tually recurs (Wiltshaw et al, 1986).
One recent advance in the chemotherapy treatment of ovarian
cancer has been the introduction of paclitaxel, a plant alkaloid
derived from the bark of Taxus brevifolia, the Pacific yew tree.
Paclitaxel has been evaluated in different trial settings, and
response rates of 16-30% have been reported in platinum-resistant
patients (Caldas and Mcguire, 1993; Trimble et al, 1993;
Eisenhauer et al, 1994). These results are similar to the findings of
other single-agent trials for refractory disease, with 25-40%
overall response to cisplatin, one of the most effective drugs for
ovarian cancer (Wiltshaw et al, 1979). This has encouraged the use
of paclitaxel in combination with drugs with established activity.
Cisplatin plus paclitaxel has been compared with cisplatin plus
cyclophosphamide in previously untreated ovarian cancer patients.
The response rates were significantly greater in the cisplatin plus
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paclitaxel arm with improved disease-free and overall survival
(McGuire et al, 1993, 1996).
Carboplatin, an analogue of cisplatin, has proved to be equally
effective in the treatment of ovarian cancer (Adams et al, 1989;
Alberts et al, 1992). Unlike cisplatin, carboplatin has few non-
haematological side-effects and predictable myelosuppression is
its dose-limiting toxicity (Adams et al, 1989). A phase I study with
a fixed dose of paclitaxel of 135 mg m-2 given over 24 h and with
escalating doses of carboplatin showed that the maximum toler-
ated area under the plasma concentration-time curve (AUC) ofthe
latter drug was 7.5 mg ml min (Ozols et al, 1993).
In the present study, paclitaxel was given as a 3-h infusion
immediately followed by carboplatin as a 30-min infusion. The
dose of carboplatin was individualized to a target AUC of 7 mg
ml min. The starting dose of paclitaxel was based on a previous
report (Ozols et al, 1993), with administration over 24 h, and on
the evidence that toxicity was less when the drug was administered
over 3 h (Eisenhauer et al, 1994). Our aims were firstly to deter-
mine the toxicity profile of paclitaxel at escalating dose levels
when combined with a standard AUC of carboplatin, secondly to
establish the dose-limiting toxicity of the combination of the two
drugs and, finally, to study the relationship between their pharma-
cokinetics and toxicity.
PATIENTS AND METHODS
Eligibility
Twelve patients with ovarian cancer were entered into this trial
between April 1994 and April 1995. All patients met the following
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inclusion criteria: histologically proven epithelial cancer of the
ovary, chemonaive patients, aged between 18-75 years inclusive,
ECOG performance status of2, life expectancy ofat least 12 weeks,
absolute neutrophil count (ANC) > 1.5 x 109 1-', platelet count >
100 x l10 1-', total bilirubin 1.25 x upper normal limit (< 2.5 x if
due to metastases), serum creatinine < 2 x upper limit ofnormal.
Exclusion criteria included brain metastases or leptomeningeal
involvement, past or current history of other neoplasm, except
curatively treated carcinoma in situ of cervix and non-melanoma
skin cancer, serious cardiac disease, documented myocardial
infarction within 6 months before entry, second- or third-degree
heart block, active infection or history of prior allergic reaction
to drugs formulated with Cremophor as an ingredient (e.g. cyclo-
sporine or vitamin K).
Treatment was to be discontinued if patients experienced unre-
solved toxicity, disease progression or hypersensitivity reaction.
Follow-up of disease status was performed at 3 months, 6 months
and up to 2 years following study completion.
All patients provided written informed consent (approved by the
local ethics committee) before starting treatment. A summary of
patient characteristics and treatment is given in Table 1.
Treatment protocol
All patients received a full clinical assessment not less than 2
weeks before entry into the sudy. With the exception of patient 6,
who had only exploratory laporotomy, all patients had debulking
surgery before treatment. Patient 6 had surgery after three cycles
of treatment, after which the full course of chemotherapy was
completed.
Paclitaxel (Taxol, Bristol-Myers Squibb) was supplied as a
concentrated sterile solution of 6 mg ml-' in a 5-ml vial in poly-
oxylated castor oil (Cremophor EL) 50% and dehydrated alcohol
USP 50%. The contents of the vial were diluted and administered
as a continuous infusion in 500 ml of5% dextrose/water through a
peripheral line with an in-line filter. Carboplatin (Paraplatin,
Bristol-Myers Squibb) was provided as lyophilized powder.
Immediately before use, the drug was reconstituted with 15 ml of
sterile water or 5% dextrose and diluted in 250 ml of5% dextrose.
The sequence ofadministration ofthe drugs was always paclitaxel
followed by carboplatin.
All patients received 20 mg oral dexamethasone, 12 h and 6 h
before treatment, and cimetidine 300 mg and chlorpheniramine 10
mg by intravenous injection, 10 min before paclitaxel infusion.
The starting dose of paclitaxel was 150 mg m-2, increased in
cohorts ofthree patients at each level.
Dose level -1 135 mg m-2
Dose level 0 150 mgm-2 patients 1-3
Dose level 1 175 mg m-2 patients 4-6
Dose level 2 200 mg m-2 patients 7-9
Dose level 3 225 mg m-2 patients 10-12
Up to three further patients were to be entered at a dose-level if a
dose-limiting toxicity occurred. The dose of carboplatin was
calculated using the Calvert formula (Calvert et al, 1989):
Dose (mg) = target AUC (mg ml-' min) x (GFR + 25)
Glomerular filtration rate (GFR) (ml min-') was determined using
the clearance of [51Cr] EDTA. The target AUC of carboplatin was
7 mg ml-' min All doses ofcarboplatin were given over 30 min by
intravenous infusion.
Table 1 Patient and disease characteristics
Patient characteristics
Number of courses assessable (median per patient) 66 (6)
Age in years (median) 32-72 (58)
Performance status (median) 0-2 (1)
Histology
Moderately-poorly differentiated
Endometrioid adenocarcinoma 4
Serous cystadenocarcinoma 3
Clear cell carcinoma 2
Mucinous adenocarcinoma 1
Adenocarcinoma 1
Poorly differentiated
Adenocarcinoma 1
Stage
llb 1
Ilc 3
III 6
IV 2
Residual disease (CT abdomen and pelvis)
None 6
Minimal 1
2-5cm 2
>5 cm 1
Liver metastases 2
The above schedule was to be modified according to haemato-
logical toxicity. Dose reduction was to be performed if ANC
dropped below 0.5 x l09 1-l and lasted for 7 days or more, or if
grade 4 thrombocytopenia occurred requiring platelet transfusion.
The chemotherapy cycles were given at 4-weekly intervals.
Granulocyte colony stimulating factor (GCSF) was to be adminis-
tered only if clinically indicated. Nausea and vomiting were
controlled with ondansetron.
Evaluation of toxicity and response
Toxicity was assessed for each cycle using WHO criteria. Weekly
blood counts were performed to evaluate the haematological and
biochemical profiles. Physical examination was carried out on day
1 of each cycle. Tumour measurements (when applicable) were
made every cycle by physical examination, every month by CA
125 and every three cycles by computerized tomography (CT)
scans. Clinical response of the tumour was assessed according to
UICC criteria.
Although this was a dose-finding study, patients with evaluable
disease were assessed for response, using the following criteria:
Complete response (CR) Disappearance of all clinical
evidence oftumour, determined by
two observations not less than 4
weeks apart.
Partial response (PR) 50% or greater decrease in the sum
ofproducts ofmeasured indicator
lesions with no simultaneous
increase in the size of any lesion or
appearance of new lesions.
Stable disease (SD) Response less than 50%, steady
state of response or progression less
than progressive disease (PD).
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Progressive disease (PD) Unequivocal increase of at least
25% in the product of measured
lesions.
Marker responses were determined as follows:
CR Complete normalization ofCA 125, lasting for more
than 4 weeks.
PR Decrease of CA 125 levels to less than 50% of
pretreatment level for more than 4 weeks.
SD Less than 50% reduction or less than 25% increase in
CA 125 levels.
PD More than 50% increase in CA 125 levels.
NE Pretreatment level is normal (< 35 kUL-') or less than
100 kUL-'.
The maximum tolerated dose was defined as that which caused
ANC less than 0.5 x 109 1-l lasting more than 7 days, neutropenic
sepsis, grade 4 thrombocytopenia, non-haematological toxicity
(Grade 3 or greater) or absence of recovery from toxicity at
scheduled retreatment in three or more of six patients treated at
that dose level.
Pharmacokinetic studies
Methods
Ofthe 12 patients enrolled in the study, nine were willing and able
to undergo collection of plasma for pharmacokinetic analysis.
Samples of blood (10 ml) were taken at times before, during and
up to 19 h after infusion of paclitaxel and anticoagulated with
EDTA. Plasma was separated immediately and stored at -20°C
until analysis. Urine was collected and stored at -20°C or was
treated with Cremophor/ethanol to give a final concentration of
solubilizing agents of 10%.
Samples and standards were analysed by an HPLC method
similar to that described by Huizing et al (1993). Briefly, stan-
dards of paclitaxel in plasma (0.02-10 .tg ml-') were prepared by
serial dilution of a stock solution in methanol. A 0.5-ml aliquot of
each sample or standard was mixed with 0.5 ml of 0.02 M ammo-
nium acetate buffer (pH 5.0) and centrifuged at 1000 r.p.m. for 10
min before extracting. Samples were extracted using end-capped
cyano Isolute columns (IST, Mid-Glamorgan, UK), precondi-
tioned with 2 ml of methanol followed by 2 ml of 0.02 M ammo-
nium acetate buffer (pH 5.0). After application of the buffered
sample, the column was washed with 4 ml ofbuffer followed by 2
ml of 20% methanol in buffer and 1 ml of isohexane. Analytes
were eluted into clean tubes using 2 ml of 0.1% triethylamine
in acetonitrile. The eluant was evaporated to dryness under
nitrogen at 30°C. Samples were reconstituted in 200 gl of 50%
acetonitrile/buffer mixture, mixing each sample for 20 sec on a
vortex mixer.
The HPLC system consisted of a Waters pump (Milford, MA,
USA) at 1.0 ml min-', a Pye Unicam PU 4021 dual wavelength UV
detector (Cambridge, UK) at 227 and 235 nm. The column was
a 250 x 4.6 mm APEX C65-,u column (Jones, Mid-Glamorgan,
UK), protected with a pelicular C,8 precolumn. The mobile phase
was a 50% mixture of acetonitrile and 0.02 M ammonium acetate
buffer (pH 5.0).
Urine was analysed as for plasma except that buffered samples
(I ml) were extracted into I-chlorobutane (5 ml), the organic phase
separated and the solvent evaporated before reconstitution and
chromatography.
Total platinum was determined in samples taken 24 h after the
start of administration using flameless atomic absorption spec-
trophotometry (Harland et al, 1984). This was used to calculate the
free platinum AUC using a previously published method (Ghazal-
Aswad et al, 1996).
The pharmacokinetics of paclitaxel was determined by model-
independent analysis with clearance and volume of distribution at
steady-state estimated by moment analysis (Gibaldi and Perrier,
1982). Terminal half-life was estimated by log-linear regression of
the last four data points. In addition, a two-compartment model
was fitted to each data set using Adapt II, release 3 (D'Argenio
and Schumitsky, 1990). Parameter estimates for each individual
were used to calculate durations for which plasma concentrations
of paclitaxel exceeded thresholds for pharmacological effect of
0.05 .tM (Gianni et al, 1995) and 0.1 tM (Huizing et al, 1995).
RESULTS
A total of 12 patients received 66 courses at four dose levels. One
patient was withdrawn from the study because of peripheral
neuropathy. A second patient, who had presented with stage IV
disease, had evidence of progression after the second cycle of
treatment and was withdrawn from study.
Analysis of toxicity
Overall, the treatment was well tolerated. Ten patients completed
the treatment of six cycles each.
Haematological toxicity
The major haematological toxicity observed was neutropenia
(Table 2). Nadir neutrophil counts were mostcommonly seen at day
14, with some degree of recovery by day 21. Nineteen per cent of
courses resulted in neutrophil nadirs less than 0.5 x 109 1-1 (Grade
4). Neutropenia was most marked in patients treated at the highest
dose level (Table 2). Despite the degree ofneutropenia, none ofthe
patients developed any consequent clinical problems. Admini-
stration of GCSF was not necessary in any case. Treatment had to
be deferred by 1 week in one patient (dose level 2, course 5) as a
result ofleucopenia on the day oftreatment (WBC 2.3 x 109 1-').
The nadir for platelets was also seen at day 14. Thrombo-
cytopenia (WHO grade 3 or 4) was seen in 5 out of 16 courses at
dose level 0, and one dose level reduction was required for patient
3. However, at a dose of paclitaxel of 175 mg m-2, a significant
drop in platelets was seen in only 1 of 18 courses. The drop in
platelet count was least at this dose level (Table 2). Two patients
required platelet transfusions, one on two occasions.
It should be noted that some patients consistently developed
grade 3 or 4 haematological toxicity throughout their treatment,
while others at the same dose level showed only minimal toxicity.
Anaemia was not a major problem.
Non-haematological toxicity
Alopecia was seen in all patients and was total. The majority lost
their hair by course 3 of treatment. The onset of hair loss was quite
sudden in some patients. Peripheral neuropathy was the other
predominant toxicity. Patient 1, who was withdrawn from the study,
developed tingling in the fingers of both hands after the first course
of treatment. By the time four courses were completed, symptoms
had progressed, and paraesthesia had developed with numbness in
fingers and toes. On examination, there was areduction in sensations
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Table 2 Haematological toxicities of carboplatin plus escalating doses of paclitaxel: numbers of courses at each toxicity grade
Dose level Patient Total no. Neutropenia Thrombocytopenia Comments
no. of courses (WHO grade) (WHO grade)
0 1 2 3 4 0 1 2 3 4
0.150mgm-2 1 4 0 1 2 1 0 1 0 3 0 0
2 6 0 0 0 6 0 3 2 0 1 0
3 6 0 1 1 4 0 0 0 2 3 1 (Platelet transfusion x 1) DR
1.175mgm-2 4 6 0 0 1 3 2 2 0 3 1 0
5 6 0 1 3 2 0 6 0 0 0 0
6 6 0 0 0 5 1 5 0 1 0 0
2.200 mg m-2 7 2 1 0 1 0 0 2 0 0 0 0
8 6 0 0 1 4 1 1 0 1 1 3 (Platelet transfusion x 3) DR
9 6 0 1 2 1 2 2 3 1 0 0
3.225 mg m-2 10 6 0 0 0 1 5 2 3 1 0 0
11 6 0 0 0 3 3 0 0 1 2 3
12 6 0 0 1 3 2 1 1 3 1 0
DR dose reduction.
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Figure 1 Overall incidence of non-haematological toxicities of paclitaxel in
combination with a fixed AUC of carboplatin
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Figure 2 Calculated AUC of carboplatin at different dose levels of paclitaxel.
Dotted line shows target AUC
(patient 12) had more severe (Grade 3) vomiting, requiring the
addition of lorazepam and prochlorperazine. All except two
patients had mild myalgia from day 2 to 6 during the first week
after treatment. This was relieved by non-steroidal anti-inflamma-
tory drugs. Cardiotoxicity as such was not seen. Two patients, who
s . were known to be hypertensive before starting treatment,
* complained of mild dizziness for a few days after treatment. One
patient (patient 8) developed a pulmonary embolism and needed
anticoagulants, another (patient 10) suffered a deep vein throm-
, , , , bosis of the leg. Other toxicities were mild and only occasionally
125 150 175 200 225 encountered, e.g. mucositis, constipation, diarrhoea and hyperten-
sion. As all the patients received prophylactic medication, no
Paclitaxel dose (mg in2 hypersensitivity reaction attributable to paclitaxel was observed.
,learance of paclitaxel at different dose levels No hepatic or renal toxicity was encountered.
and hyporeflexia. All other patients had paraesthesias, but few had
numbness of fingers and toes. Subjective symptoms of peripheral
neuropathy were more frequent than wouldbe suggestedby physical
examination. Neurotoxicity appeared to be cumulative, but was not
related to dose.
Three patients complained of nausea and vomiting (Figure 1)
which was controlled with ondansetron, however one of these
Analysis of pharmacokinetics
Carboplatin pharmacokinetics
The AUC offree platinum was estimated in each patient using the
total platinum in a sample taken 24 h after administration. In the
nine patients for whom plasma samples were available, the esti-
mated AUC was, on average, equal to the target AUC, but with
some variation (mean ± s.d.; 7.0±1.4 mg ml min). There did not
British Journal ofCancer (1997) 75(2), 287-294
90
80
70
0
250
0 a-0
ir.0.
20.
10.
E
.C
co E a)
n co
CD ao
aL
350
300
250
200
150
100
50
01
Figure 3 C
0 CancerResearch Campaign 1997
.. <:Phase I study ofpaclitaxel andcarboplatin 291
Table 3 Pharmacokinetics of paclitaxel and its 6-hydroxy metabolite when administered in combination with carboplatin
Patient Surface Paclitaxel Peaklevel AUC Half-life Vds, Cl Excretion in urine AUC6-hydroxy
area (m-2) dose (mg m-2) (gg ml-') (jg ml-' min) (min) (I m-2) (ml min-' m-2) (% of dose) metabolite(gg ml-' min)
1 1.8 150 2.6 481 408 74 312 3.6 26
2 2.1 150 2.9 507 470 78 296 3.3 20
3 1.7 150 2.8 439 602 113 342 5.8 16
4 1.5 175 3.2 607 366 68 288 3.6 14
5 1.9 175 4.5 772 669 90 227 1.9 33
8 1.5 200 7.7 1489 503 61 134 2.9 52
9 1.7 200 7.1 1433 343 28 141 5.4 46
10 1.6 225 6.9 1787 361 38 126 3.4 106
12 1.7 225 7.6 1569 384 30 143 3.2 113
Vd,s, volume of distribution atsteady state; Cl, clearance.
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Figure 4 Plasma concentrations of paclitaxel and its 6-hydroxy metabolite in
patient 10 (dose 225 mg m-2). -U Paclitaxel; -* 6-hydroxypaclitaxel
Table 4 Response to carboplatin in combination with escalating doses of
paclitaxel - Tumour marker levels (CA 125)
CAl25 (kU 1-')
Dose level Patient no. Pretreatment" Post-treatmentb
0.150 mg m-2 1 240 9
2 115 18
3 102 27
1.175 mg m-2 4 46 40
5 67 18
6 540 8
2.200 mg m-2 7 171 108
8 17 8
9 197 7
3.225 mg m-2 10 550 31
11 221 21
12 195 9
aWithin 2 weeks of entering trial. bAfter completion of up to six courses of
therapy.
appear to be any influence ofpaclitaxel dose on the AUC of free
platinum (Figure 2).
Paclitaxelpharmacokinetics:
As for carboplatin, plasma samples were available for only nine
patients. Paclitaxel reached a maximum plasma concentration
(2.6-7.7 jg ml-') at the end ofthe infusion and was still detectable
in every patient 24 h later (0.02-0.08 ,ug ml-'). Although a linear
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Figure 5 Graph of percentage decrease in ANC against time for which
paclitaxel concentrations in plasma exceed 0.05gM (*) or 0.1 gM (E)
two-compartment model appeared to be adequate to describe the
pharmacokinetics of paclitaxel in individual patients (data not
shown), comparison of clearance at the different dose levels
revealed obvious non-linearity in elimination over this dose range
(Figure 3). For a 33% increase in dose from 150 to 200 mg m-2, the
AUC increased threefold (mean 476 jig ml-' min-' to 1461 jg ml-'
min). Volume ofdistribution appeared to be dose dependent (Table
3), but calculation ofthis parameter is not reliable in the presence of
non-linear elimination. Terminal half-life did not appear to be dose-
dependent and varied from 5.7 h up to 11.1 h (Table 3).
Only a small fraction (< 6%) of the administered dose was
collected in the urine as unchanged paclitaxel (Table 3). Meta-
bolite peaks were noted in chromatograms from both plasma and
urine and were tentatively identified, by comparison with
published retention times (Huizing et al, 1993), as the 6-hydroxy
and the 3'-phenyl-hydroxy metabolites described previously.
Approximate AUC values for the 6-hydroxy metabolite are given
in Table 3. A plot of plasma concentration against time for the
parent drug and the 6-hydroxy metabolite in one patient is shown
in Figure 4.
The durations for which paclitaxel concentrations exceeded
previously identified thresholds for pharmacological effect were
calculated. The duration above 0.1 jIM ranged from 775 to 1665
min, while that above 0.05 jM went from 1125 to 2115 min. There
were cleardifferences among patients in the rankorderofthe dura-
tion above these two threshold concentrations; and these were due
to interindividual variations in the elimination rates post-infusion.
There was no clear relationship between toxicity and time above
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these threshold concentrations (Figure 5). This may be because
only a narrow range of toxicities was observed in only a small
number ofpatients.
Analysis of response
All of the patients were assessed for response by clinical,
biochemical and radiological parameters. In many studies, serum
CA 125 tumour marker level has been considered a reliable
predictor of response to treatment (McGuire et al, 1989; Einzig et
al 1992; Kohn et al, 1994; Tuxen et al, 1995). Of the twelve
patients who entered the study, nine patients had pretreatment CA
125 levels of .100 kU l-' (normal range: up to 35 kU 1-'). In all
except one of these patients, the levels normalized during treat-
ment (Table 4).
Six patients had normal base line CT scans. One of these
patients, who had umbilical metastases at presentation and who
could not have complete debulking at the time oforiginal surgery,
progressed and was taken off the study after two courses. In six
patients, residual disease was documented by CT scans before
starting treatment. CT scans at the end of treatment showed CR in
five of the patients with residual disease. Patient 6 had debulking
surgery after course 3, before completing the final three cycles of
treatment. At laproscopy, after finishing treatment, there was no
evidence ofdisease.
Despite an initial response, six patients have relapsed since
finishing chemotherapy. Two of these patients were treated at the
first dose level (150 mg m-2). Patient 1, who relapsed 9 months
after her last treatment, had been withdrawn from the study
because of neurotoxicity. After four courses of the combined
regimen, this patient also received two further courses of single
agent carboplatin (AUC 7 mg ml- min). Patients 2, 4, 6, 10 and 12
relapsed between 2 and 16 months after starting treatment. At
present six patients remain disease free at between 15 and 24
months after the start of treatment.
DISCUSSION
Until recently, chemotherapy with platinum regimens has been the
treatment of choice for ovarian cancer. However, since the
discovery ofpaclitaxel there has been considerable enthusiasm for
combination chemotherapy based on paclitaxel with other agents
(Kohn et al, 1993; Bruckner et al, 1994). The response rates and
toxicity profiles of paclitaxel and cisplatin have been assessed
(Rowinsky et al, 1991). The first combination of paclitaxel and
cisplatin showed that there were clinically significant interactions
between the two drugs (Rowinsky et al, 1991). Different schedules
ofdrug sequences demonstrated more profound myelosuppression
when cisplatin was given before paclitaxel. Neutropenia was the
dose-limiting toxicity at doses ofcisplatin of75 mg m-2 and pacli-
taxel of 135 mg m-2. In a later study when GCSF (granulocyte
colony-stimulating factor) was used, the dose of paclitaxel could
be escalated to 250 mg m-2 with cisplatin at 75 mg m-2, and
neuropathy became the major toxicity (Rowinsky et al, 1993).
Cisplatin is known to be neurotoxic and the effects ofpaclitaxel on
the neuromuscular system are well documented (Sarosy et al,
1992). A 3-h infusion ofpaclitaxel administered to patients previ-
ously treated with cisplatin induced moderate neurotoxicity and
pathologically proven axonal damage (Cavaletti et al, 1995). This
indicates that damage to the neurological system could be a poten-
tial problem with the combination of paclitaxel and cisplatin.
Paclitaxel is also being studied in combination with carboplatin
(Ozols et al, 1993; Bolis et al, 1995; Bookman et al, 1995;
Lhomme et al, 1995), but the toxicity profile of these drugs given
together has yet to be properly defined. Previous phase I studies of
carboplatin and paclitaxel have used the Jellife formula or creati-
nine clearance to determine the GFR and to calculate the dose of
carboplatin. The present study is one of the first of this combina-
tion, in which the dose of carboplatin was calculated using
[51Cr]EDTA clearance to determine the glomerular filtration rate
(GFR), and it would be expected to produce a very predictable
level ofthrombocytopenia (Calvert, 1994).
The degree of thrombocytopenia induced by the two drugs
together was less than would have been expected if carboplatin
had been given alone. This interesting observation, which has also
been made by other groups (Bunn and Kelly, 1995; Kearns et al,
1995), is suggestive ofa protective effect ofpaclitaxel on platelets.
The mechanism underlying this observation is not yet clear,
however there is some evidence that paclitaxel, like lipopolysac-
charides, causes increased expression ofthe cytokine interleukin 1
in paclitaxel-activated macrophages (Carboni et al, 1993; O'Brien
et al, 1995). It is possible that, by stimulation of cytokine produc-
tion, paclitaxel causes increased levels of thrombopoieitin, thus
ameliorating the degree of thrombocytopenia. Another possible
mechanism for the protection ofplatelets is the very high degree of
binding of paclitaxel to tubulin in these cells (Wild et al, 1995).
This binding might, in some way, stabilize the thrombocytes
(Crook and Crawford, 1989) and either protect them from plat-
inum-induced damage or prolong circulation time.
The effect of the sequence of drug administration on haemato-
logical toxicity have been investigated (Rowinsky et al, 1991). In a
study of cisplatin (50 or 75 mg m-2) combined with paclitaxel
(110-200 mg m-2 as a 24-h infusion) and with the order of admin-
istration randomized, more profound myelosuppression was
observed when cisplatin was given before paclitaxel. Pharma-
cological studies showed that paclitaxel clearance was 25% lower
with this sequence of drugs, which may partly explain this clini-
cally significant interaction. No such sequence-dependent interac-
tion has been reported with carboplatin plus paclitaxel, but this has
not yet been investigated systematically.
A large study, designed specifically to determine the optimal
dose and schedule for paclitaxel administration, has shown that a
3-h infusion is less myelosuppressive than a 24-h infusion and that
a dose of 175 mg m-2 produces a greater anti-tumour effect
(Eisenhauer et al, 1994). As a result of this, paclitaxel (as a single
agent) is usually given at a dose of 175 mg m-2 over 3 h. In this
phase I study, paclitaxel administered over 3 h, in combination
with carboplatin, was dose escalated from 150 to 225 mg m-2. The
maximum tolerated dose (MTD) was defined as the dose at which
three or more patients developed grade 4 neutropenia or thrombo-
cytopenia lasting for more than 7 days. This level of toxicity was
not encountered, and so the MTD was not determined in this study.
It is encouraging to note that although the toxicity ofthis combi-
nation is low, it has been reported that the majority of patients
show some tumour response (Ozols et al, 1993). The promising
response rates may be owing to the fact that the response to single-
agent carboplatin treatment is strongly related to the expression of
mutant or wild type p53 gene in the tumour. Although ovarian
cancer cell lines with mutant p53 genes undergo apotosis in
response to both paclitaxel and cisplatin (Havrilesky et al, 1995),
platinum-resistant tumours are more likely to have evidence of
p53 mutation (Al-Azraqi et al, 1995). Preclinical evidence
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suggests that paclitaxel may produce apoptosis by ap53-indepen-
dent mechanism (Woods et al, 1995). Thus, this combination of
two drugs with complementary activity could prove advantageous
in the treatment of a tumour cell population with heterogeneous
p53 expression.
Although not definite, there may be a relationship between pacli-
taxel dose and anti-tumour activity (Sarosy et al, 1992; Nabboltz et
al, 1993; Belani et al, 1995; Bunn and Kelly, 1995). Non-linear
pharmacokinetics could partly explain this finding. Ifsuch a dose -
response effect is clearly established, it would be logical to give
higher doses of paclitaxel with the support of growth factors. In a
recent review oftreatment for ovarian cancer, it was recommended
that the standard first-line chemotherapy for advanced ovarian
carcinoma should be a combination of paclitaxel plus a platinum
compound (Thigpen et al, 1994). Our study, albeit with only a
small number of patients, suggests that paclitaxel plus carboplatin
may have an advantage over the combination of paclitaxel and
cisplatin in terms oftoxicity profile. Further studies with increased
dose intensity, possibly supported with GCSF, are warranted, with
close monitoring ofthe pharmacology and toxicity ofboth agents.
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